Search

Your search keyword '"Guivel-Benhassine, Florence"' showing total 202 results
Start Over Author "Guivel-Benhassine, Florence"
202 results on '"Guivel-Benhassine, Florence"'

1. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion

Author

Planas, Delphine, Staropoli, Isabelle, Michel, Vincent, Lemoine, Frederic, Donati, Flora, Prot, Matthieu, Porrot, Francoise, Guivel-Benhassine, Florence, Jeyarajah, Banujaa, Brisebarre, Angela, Dehan, Océane, Avon, Léa, Bolland, William Henry, Hubert, Mathieu, Buchrieser, Julian, Vanhoucke, Thibault, Rosenbaum, Pierre, Veyer, David, Péré, Hélène, Lina, Bruno, Trouillet-Assant, Sophie, Hocqueloux, Laurent, Prazuck, Thierry, Simon-Loriere, Etienne, and Schwartz, Olivier

Published
2024
Full Text
View/download PDF

2. TMPRSS2 is a functional receptor for human coronavirus HKU1

Author

Saunders, Nell, Fernandez, Ignacio, Planchais, Cyril, Michel, Vincent, Rajah, Maaran Michael, Baquero Salazar, Eduard, Postal, Jeanne, Porrot, Francoise, Guivel-Benhassine, Florence, Blanc, Catherine, Chauveau-Le Friec, Gaëlle, Martin, Augustin, Grzelak, Ludivine, Oktavia, Rischa Maya, Meola, Annalisa, Ahouzi, Olivia, Hoover-Watson, Hunter, Prot, Matthieu, Delaune, Deborah, Cornelissen, Marion, Deijs, Martin, Meriaux, Véronique, Mouquet, Hugo, Simon-Lorière, Etienne, van der Hoek, Lia, Lafaye, Pierre, Rey, Felix, Buchrieser, Julian, and Schwartz, Olivier

Published
2023
Full Text
View/download PDF

3. Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2

Author

Planchais, Cyril, Fernández, Ignacio, Chalopin, Benjamin, Bruel, Timothée, Rosenbaum, Pierre, Beretta, Maxime, Dimitrov, Jordan D., Conquet, Laurine, Donati, Flora, Prot, Matthieu, Porrot, Françoise, Planas, Delphine, Staropoli, Isabelle, Guivel-Benhassine, Florence, Baquero, Eduard, van der Werf, Sylvie, Haouz, Ahmed, Simon-Lorière, Etienne, Montagutelli, Xavier, Maillère, Bernard, Rey, Félix A., Guardado-Calvo, Pablo, Nozach, Hervé, Schwartz, Olivier, and Mouquet, Hugo

Published
2024
Full Text
View/download PDF

4. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies

Author

Planas, Delphine, Bruel, Timothée, Staropoli, Isabelle, Guivel-Benhassine, Florence, Porrot, Françoise, Maes, Piet, Grzelak, Ludivine, Prot, Matthieu, Mougari, Said, Planchais, Cyril, Puech, Julien, Saliba, Madelina, Sahraoui, Riwan, Fémy, Florent, Morel, Nathalie, Dufloo, Jérémy, Sanjuán, Rafael, Mouquet, Hugo, André, Emmanuel, Hocqueloux, Laurent, Simon-Loriere, Etienne, Veyer, David, Prazuck, Thierry, Péré, Hélène, and Schwartz, Olivier

Published
2023
Full Text
View/download PDF

6. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

Author

Bruel, Timothée, Hadjadj, Jérôme, Maes, Piet, Planas, Delphine, Seve, Aymeric, Staropoli, Isabelle, Guivel-Benhassine, Florence, Porrot, Françoise, Bolland, William-Henry, Nguyen, Yann, Casadevall, Marion, Charre, Caroline, Péré, Hélène, Veyer, David, Prot, Matthieu, Baidaliuk, Artem, Cuypers, Lize, Planchais, Cyril, Mouquet, Hugo, Baele, Guy, Mouthon, Luc, Hocqueloux, Laurent, Simon-Loriere, Etienne, André, Emmanuel, Terrier, Benjamin, Prazuck, Thierry, and Schwartz, Olivier

Published
2022
Full Text
View/download PDF

7. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study

Author

Bruel, Timothée, Pinaud, Laurie, Tondeur, Laura, Planas, Delphine, Staropoli, Isabelle, Porrot, Françoise, Guivel-Benhassine, Florence, Attia, Mikaël, Pelleau, Stéphane, Woudenberg, Tom, Duru, Cécile, Koffi, Aymar Davy, Castelain, Sandrine, Fernandes-Pellerin, Sandrine, Jolly, Nathalie, De Facci, Louise Perrin, Roux, Emmanuel, Ungeheuer, Marie-Noëlle, Van Der Werf, Sylvie, White, Michael, Schwartz, Olivier, and Fontanet, Arnaud

Published
2022
Full Text
View/download PDF

8. C910 chemical compound inhibits the traffiking of several bacterial AB toxins with cross-protection against influenza virus

Author

Wu, Yu, Mahtal, Nassim, Paillares, Eléa, Swistak, Léa, Sagadiev, Sara, Acharya, Mridu, Demeret, Caroline, Werf, Sylvie Van Der, Guivel-Benhassine, Florence, Schwartz, Olivier, Petracchini, Serena, Mettouchi, Amel, Caramelle, Lucie, Couvineau, Pierre, Thai, Robert, Barbe, Peggy, Keck, Mathilde, Brodin, Priscille, Machelart, Arnaud, Sencio, Valentin, Trottein, François, Sachse, Martin, Chicanne, Gaëtan, Payrastre, Bernard, Ville, Florian, Kreis, Victor, Popoff, Michel-Robert, Johannes, Ludger, Cintrat, Jean-Christophe, Barbier, Julien, Gillet, Daniel, and Lemichez, Emmanuel

Published
2022
Full Text
View/download PDF

9. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Author

Planas, Delphine, Saunders, Nell, Maes, Piet, Guivel-Benhassine, Florence, Planchais, Cyril, Buchrieser, Julian, Bolland, William-Henry, Porrot, Françoise, Staropoli, Isabelle, Lemoine, Frederic, Péré, Hélène, Veyer, David, Puech, Julien, Rodary, Julien, Baele, Guy, Dellicour, Simon, Raymenants, Joren, Gorissen, Sarah, Geenen, Caspar, Vanmechelen, Bert, Wawina-Bokalanga, Tony, Martí-Carreras, Joan, Cuypers, Lize, Sève, Aymeric, Hocqueloux, Laurent, Prazuck, Thierry, Rey, Félix A., Simon-Loriere, Etienne, Bruel, Timothée, Mouquet, Hugo, André, Emmanuel, and Schwartz, Olivier

Published
2022
Full Text
View/download PDF

11. Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

Author

Saunders, Nell, Planas, Delphine, Bolland, William H., Rodriguez, Christophe, Fourati, Slim, Buchrieser, Julian, Planchais, Cyril, Prot, Matthieu, Staropoli, Isabelle, Guivel-Benhassine, Florence, Porrot, Françoise, Veyer, David, Péré, Hélène, Robillard, Nicolas, Saliba, Madelina, Baidaliuk, Artem, Seve, Aymeric, Hocqueloux, Laurent, Prazuck, Thierry, Rey, Felix A., Mouquet, Hugo, Simon-Lorière, Etienne, Bruel, Timothée, Pawlotsky, Jean-Michel, and Schwartz, Olivier

Published
2022
Full Text
View/download PDF

12. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Author

Planas, Delphine, Veyer, David, Baidaliuk, Artem, Staropoli, Isabelle, Guivel-Benhassine, Florence, Rajah, Maaran Michael, and Planchais, Cyril

Subjects
Medical research, Medicine, Experimental, Immune response -- Research, Monoclonal antibodies -- Research, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India.sup.1-5. Since then, it has become dominant in some regions of India and in the UK, and has spread to many other countries.sup.6. The lineage includes three main subtypes (B1.617.1, B.1.617.2 and B.1.617.3), which contain diverse mutations in the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein that may increase the immune evasion potential of these variants. B.1.617.2--also termed the Delta variant--is believed to spread faster than other variants. Here we isolated an infectious strain of the Delta variant from an individual with COVID-19 who had returned to France from India. We examined the sensitivity of this strain to monoclonal antibodies and to antibodies present in sera from individuals who had recovered from COVID-19 (hereafter referred to as convalescent individuals) or who had received a COVID-19 vaccine, and then compared this strain with other strains of SARS-CoV-2. The Delta variant was resistant to neutralization by some anti-NTD and anti-RBD monoclonal antibodies, including bamlanivimab, and these antibodies showed impaired binding to the spike protein. Sera collected from convalescent individuals up to 12 months after the onset of symptoms were fourfold less potent against the Delta variant relative to the Alpha variant (B.1.1.7). Sera from individuals who had received one dose of the Pfizer or the AstraZeneca vaccine had a barely discernible inhibitory effect on the Delta variant. Administration of two doses of the vaccine generated a neutralizing response in 95% of individuals, with titres three- to fivefold lower against the Delta variant than against the Alpha variant. Thus, the spread of the Delta variant is associated with an escape from antibodies that target non-RBD and RBD epitopes of the spike protein. The SARS-CoV-2 Delta variant partially evades neutralization by several monoclonal antibodies and by sera from individuals who have had COVID-19, but two doses of anti-COVID-19 vaccines still generate a strong neutralizing response., Author(s): Delphine Planas [sup.1] [sup.2] , David Veyer [sup.3] [sup.4] , Artem Baidaliuk [sup.5] , Isabelle Staropoli [sup.1] , Florence Guivel-Benhassine [sup.1] , Maaran Michael Rajah [sup.1] [sup.6] , Cyril [...]

Published
2021
Full Text
View/download PDF

13. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Author

Planas, Delphine, Bruel, Timothée, Grzelak, Ludivine, Guivel-Benhassine, Florence, Staropoli, Isabelle, Porrot, Françoise, Planchais, Cyril, Buchrieser, Julian, Rajah, Maaran Michael, Bishop, Elodie, Albert, Melanie, Donati, Flora, Prot, Matthieu, Behillil, Sylvie, Enouf, Vincent, Maquart, Marianne, and Smati-Lafarge, Mounira

Subjects
Viral antibodies -- Physiological aspects -- Genetic aspects, Immune response -- Genetic aspects, Antibodies -- Physiological aspects -- Genetic aspects, Biological sciences, Health
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 and B.1.351 variants were first identified in the United Kingdom and South Africa, respectively, and have since spread to many countries. These variants harboring diverse mutations in the gene encoding the spike protein raise important concerns about their immune evasion potential. Here, we isolated infectious B.1.1.7 and B.1.351 strains from acutely infected individuals. We examined sensitivity of the two variants to SARS-CoV-2 antibodies present in sera and nasal swabs from individuals infected with previously circulating strains or who were recently vaccinated, in comparison with a D614G reference virus. We utilized a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection. Sera from 58 convalescent individuals collected up to 9 months after symptoms, similarly neutralized B.1.1.7 and D614G. In contrast, after 9 months, convalescent sera had a mean sixfold reduction in neutralizing titers, and 40% of the samples lacked any activity against B.1.351. Sera from 19 individuals vaccinated twice with Pfizer Cominarty, longitudinally tested up to 6 weeks after vaccination, were similarly potent against B.1.1.7 but less efficacious against B.1.351, when compared to D614G. Neutralizing titers increased after the second vaccine dose, but remained 14-fold lower against B.1.351. In contrast, sera from convalescent or vaccinated individuals similarly bound the three spike proteins in a flow cytometry-based serological assay. Neutralizing antibodies were rarely detected in nasal swabs from vaccinees. Thus, faster-spreading SARS-CoV-2 variants acquired a partial resistance to neutralizing antibodies generated by natural infection or vaccination, which was most frequently detected in individuals with low antibody levels. Our results indicate that B1.351, but not B.1.1.7, may increase the risk of infection in immunized individuals. Sera from convalescent individuals with coronavirus disease 2019 and from individuals vaccinated with BNT162b2 have reduced ability to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351, but antibody potency against the variants increases after two vaccine doses., Author(s): Delphine Planas [sup.1] [sup.2] [sup.3] , Timothée Bruel [sup.1] [sup.2] [sup.3] , Ludivine Grzelak [sup.1] [sup.2] [sup.3] [sup.4] , Florence Guivel-Benhassine [sup.1] [sup.2] [sup.3] , Isabelle Staropoli [sup.1] [sup.2] [...]

Published
2021
Full Text
View/download PDF

14. High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1

Author

Bolland, William, primary, Michel, Vincent, additional, Planas, Delphine, additional, Hubert, Mathieu, additional, Staropoli, Isabelle, additional, Guivel-Benhassine, Florence, additional, Porrot, Françoise, additional, N'Debi, Mélissa, additional, Rodriguez, Christophe, additional, Fourati, Slim, additional, Prot, Matthieu, additional, Planchais, Cyril, additional, Hocqueloux, Laurent, additional, Simon-Lorière, Etienne, additional, Mouquet, Hugo, additional, Prazuck, Thierry, additional, Pawlotsky, Jean-Michel, additional, Bruel, Timothée, additional, Schwartz, Olivier, additional, and Buchrieser, Julian, additional

Published
2023
Full Text
View/download PDF

15. SARS-CoV-2 replicates in the human testis with slow kinetics and has no major deleterious effects ex vivo

Author

Mahé, Dominique, primary, Bourgeau, Salomé, additional, da Silva, Janaina, additional, Schlederer, Julie, additional, Satie, Anne-Pascale, additional, Kuassivi, Nadège, additional, Mathieu, Romain, additional, Guillou, Yves-Marie, additional, Le Tortorec, Anna, additional, Guivel-Benhassine, Florence, additional, Schwartz, Olivier, additional, Plotton, Ingrid, additional, and Dejucq-Rainsford, Nathalie, additional

Published
2023
Full Text
View/download PDF

16. Neutralizing Antibody Levels as a Correlate of Protection Against SARS‐CoV‐2 Infection: A Modeling Analysis

Author

Lingas, Guillaume, primary, Planas, Delphine, additional, Péré, Hélène, additional, Porrot, Françoise, additional, Guivel‐Benhassine, Florence, additional, Staropoli, Isabelle, additional, Duffy, Darragh, additional, Chapuis, Nicolas, additional, Gobeaux, Camille, additional, Veyer, David, additional, Delaugerre, Constance, additional, Le Goff, Jérôme, additional, Getten, Prunelle, additional, Hadjadj, Jérôme, additional, Bellino, Adèle, additional, Parfait, Béatrice, additional, Treluyer, Jean‐Marc, additional, Schwartz, Olivier, additional, Guedj, Jérémie, additional, Kernéis, Solen, additional, and Terrier, Benjamin, additional

Published
2023
Full Text
View/download PDF

18. Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

Author

Bruel, Timothée, primary, Vrignaud, Lou-Léna, additional, Porrot, Françoise, additional, Staropoli, Isabelle, additional, Planas, Delphine, additional, Guivel-Benhassine, Florence, additional, Puech, Julien, additional, Prot, Matthieu, additional, Munier, Sandie, additional, Bolland, William Henry, additional, Soulié, Cathia, additional, Zafilaza, Karen, additional, Lusivika-Nzinga, Clovis, additional, Meledge, Marie-Laure, additional, Dorival, Céline, additional, Molino, Diana, additional, Péré, Hélène, additional, Yordanov, Youri, additional, Simon-Lorière, Etienne, additional, Veyer, David, additional, Carrat, Fabrice, additional, Schwartz, Olivier, additional, Marcelin, Anne-Geneviève, additional, Martin-Blondel, Guillaume, additional, Garcia, Magalie, additional, Giraud, Valentin, additional, Metais, Agathe, additional, Cazenave-Roblot, Fance, additional, Martellosio Anne-Marie Ronchetti, Jean-Philippe, additional, Gabas, Thomas, additional, Hadjadj, Naima, additional, Salanoubat, Célia, additional, Chabrol, Amélie, additional, Housset, Pierre, additional, Pardon, Agathe, additional, Faucon, Anne-Laure, additional, Caudwell, Valérie, additional, Roland Liblau, Latifa Hanafi, additional, Alric, Laurent, additional, Pugnet, Grégory, additional, Mourguet, Morgane, additional, Bories, Eva, additional, Bonnet, Delphine, additional, Charpentier, Sandrine, additional, Delobel, Pierre, additional, Debard, Alexa, additional, Beck, Colleen, additional, Boumaza, Xavier, additional, Fanny Lanternier, Stella Rousset, additional, Delage, Claire, additional, Pires, Elisabete Gomes, additional, Cheminant, Morgane, additional, Anthony Chauvin, Nathalie Chavarot, additional, Véronique Delcey Simon Bessis, Xavier Eyer, additional, Cresta, Mélanie, additional, Pélagie Thibaut, Romain Gueneau, additional, Nadal, Marine, additional, Siguier, Martin, additional, Bachir, Marwa, additional, Valérie Pourcher, Christia Palacios, additional, Melenotte, Cléa, additional, Faycal, Antoine, additional, Berot, Vincent, additional, Brin, Cécile, additional, Djebara, Siham, additional, Marot, Stéphane, additional, Sayon, Sophie, additional, Leducq, Vincent, additional, Malet, Isabelle, additional, Teyssou, Elisa, additional, Karine Lacombe, Adélie Gothland, additional, Aad, Yasmine Abi, additional, Chiarabini, Thibault, additional, Feliho, Raynald, additional, Valin, Nadia, additional, Brigant, Fabien, additional, Boize, Julien, additional, Thiébaud, Pierre-Clément, additional, Moreau, Marie, additional, Nathalie De Castro, Charlotte Billard, additional, Liégeon, Geoffroy, additional, Denis, Blandine, additional, Molina, Jean-Michel, additional, André Cabié, Lucia Etheve, additional, Abel, Sylvie, additional, Cabras, Ornella, additional, Guitteaud, Karine, additional, François Vincent Dubee, Sandrine Pierre-, additional, Ndiaye, Diama, additional, Pehlivan, Jonathan, additional, Phelippeau, Michael, additional, Alexandre Duvignaud, Rafael Mahieu, additional, Pistone, Thierry, additional, Desclaux, Arnaud, additional, Neau, Didier, additional, Jean-François Faucher, Charles Cazanave, additional, Festou, Benjamin, additional, Dupuy-Grasset, Magali, additional, Loustaud-Ratti, Véronique, additional, Nathan Peiffer- Smadja, Delphine Chainier, additional, Choquet, Christophe, additional, Da Conceicao, Olivia, additional, Thy, Michael, additional, Collas, Lio, additional, Godard, Cindy, additional, Bouzid, Donia, additional, Ing, Vittiaroat, additional, Pereira, Laurent, additional, Pavlowsky, Thomas, additional, RavautAntoine Asquier-Khati, Camille, additional, Boutoille, David, additional, Chauveau, Marie, additional, Deschanvres, Colin, additional, Audrey Le Bot, François Raffi, additional, Cailleaux, Marine, additional, Benezit, François, additional, Maillard, Anne, additional, Hue, Benoit, additional, François Coustilleres, Pierre Tattevin, additional, Carvalho-Schneider, Claudia, additional, Jamard, Simon, additional, Petit, Laeticia, additional, Natacha Mrozek, Karl Stefic, additional, Theis, Clément, additional, Vidal, Magali, additional, Sauvat, Léo, additional, Benjamin Lefèvre, Delphine Martineau, additional, Baronnet, Guillaume, additional, Florence Ader, Agnès Didier, additional, Perpoint, Thomas, additional, Conrad, Anne, additional, Chabert, Paul, additional, Aurélie Martin, Pierre Chauvelot, additional, Loubet, Paul, additional, Mazet, Julien, additional, Larcher, Romaric, additional, Mathilde Devaux Jérôme Frey, Didier Laureillard, additional, Woerlen, Amos, additional, Remillon, Aline, additional, Absensur-Vuillaume, Laure, additional, Albert Trinh-Duc, Pauline Bouquet, additional, Philippe Petua, Patrick Rispal, additional, Aurore Perrot, Julien Carillo, additional, Delavigne, Karen, additional, Cougoul, Pierre, additional, Dion, Jérémie, additional, Mathieu Blot, Odile Rauzy, additional, Sixt, Thibault, additional, Moretto, Florian, additional, Charles, Carole, additional, Sophie Circosta, Lionel Piroth, additional, Leger, Lydia, additional, Arulananthan, Arulvani, additional, Lascoux, Carine, additional, Valérie, Pascaline, additional, Yazdan Yazdanpanah, Leia Becam, additional, Petrov-Sanchez, Ventzislava, additional, Diallo, Alpha, additional, Le Mestre, Soizic, additional, Le Meut Isabelle Goderel, Guillaume, additional, Chau, Frédéric, additional, Soltana, Brahim, additional, Chane Tang, Jessica, additional, Guedj, Jérémie, additional, and Caille, Yvanie, additional

Published
2023
Full Text
View/download PDF

19. Neutralizing Antibody Levels as a Correlate of Protection Against SARS‐CoV‐2 Infection: A Modeling Analysis.

Author

Lingas, Guillaume, Planas, Delphine, Péré, Hélène, Porrot, Françoise, Guivel‐Benhassine, Florence, Staropoli, Isabelle, Duffy, Darragh, Chapuis, Nicolas, Gobeaux, Camille, Veyer, David, Delaugerre, Constance, Le Goff, Jérôme, Getten, Prunelle, Hadjadj, Jérôme, Bellino, Adèle, Parfait, Béatrice, Treluyer, Jean‐Marc, Schwartz, Olivier, Guedj, Jérémie, and Kernéis, Solen

Subjects
VIRAL load, POLYMERASE chain reaction, SARS-CoV-2, IMMUNOGLOBULINS, INFECTIOUS disease transmission, PLANT protection
Abstract

Although anti‐severe acute respiratory syndrome‐coronavirus 2 antibody kinetics have been described in large populations of vaccinated individuals, we still poorly understand how they evolve during a natural infection and how this impacts viral clearance. For that purpose, we analyzed the kinetics of both viral load and neutralizing antibody levels in a prospective cohort of individuals during acute infection with alpha variant. Using a mathematical model, we show that the progressive increase in neutralizing antibodies leads to a shortening of the half‐life of both infected cells and infectious viral particles. We estimated that the neutralizing activity reached 90% of its maximal level within 11 days after symptom onset and could reduce the half‐life of both infected cells and circulating virus by a 6‐fold factor, thus playing a key role to achieve rapid viral clearance. Using this model, we conducted a simulation study to predict in a more general context the protection conferred by pre‐existing neutralization titers, due to either vaccination or prior infection. We predicted that a neutralizing activity, as measured by 50% effective dose > 103, could reduce by 46% the risk of having viral load detectable by standard polymerase chain reaction assays and by 98% the risk of having viral load above the threshold of infectiousness. Our model shows that neutralizing activity could be used to define correlates of protection against infection and transmission. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals

Author

Hubert, Mathieu, primary, Guivel-Benhassine, Florence, additional, Bruel, Timothée, additional, Porrot, Françoise, additional, Planas, Delphine, additional, Vanhomwegen, Jessica, additional, Wiedemann, Aurélie, additional, Burrel, Sonia, additional, Marot, Stéphane, additional, Palich, Romain, additional, Monsel, Gentiane, additional, Diombera, Harouna, additional, Gallien, Sébastien, additional, Lopez-Zaragoza, Jose Luis, additional, Vindrios, William, additional, Taieb, Fabien, additional, Fernandes-Pellerin, Sandrine, additional, Delhaye, Maurine, additional, Laude, Hélène, additional, Arowas, Laurence, additional, Ungeheuer, Marie-Noelle, additional, Hocqueloux, Laurent, additional, Pourcher, Valérie, additional, Prazuck, Thierry, additional, Marcelin, Anne-Geneviève, additional, Lelièvre, Jean-Daniel, additional, Batéjat, Christophe, additional, Lévy, Yves, additional, Manuguerra, Jean-Claude, additional, and Schwartz, Olivier, additional

Published
2023
Full Text
View/download PDF

21. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies

Author

KU Leuven, Institut Pasteur, Fondation pour la Recherche Médicale, Agence Nationale de la Recherche (France), European Commission, Région Ile-de-France, National Institutes of Health (US), Research Foundation - Flanders, Planas, Delphine, Bruel, Timothee, Staropoli, Isabelle, Guivel-Benhassine, Florence, Porrot, Francoise, Maes, Piet, Grzelak, Ludivine, Prot, Matthieu, Mougari, Said, Planchais, Cyril, Puech, Julien, Saliba, Madelina, Sahraoui, Riwan, Femy, Florent, Morel, Nathalie, Dufloo, Jeremy, Sanjuán, Rafael, Mouquet, Hugo, Andre, Emmanuel, Hocqueloux, Laurent, Simon-Loriere, Etienne, Veyer, David, Prazuck, Thierry, Péré, Hélène, Schwartz, Olivier, KU Leuven, Institut Pasteur, Fondation pour la Recherche Médicale, Agence Nationale de la Recherche (France), European Commission, Région Ile-de-France, National Institutes of Health (US), Research Foundation - Flanders, Planas, Delphine, Bruel, Timothee, Staropoli, Isabelle, Guivel-Benhassine, Florence, Porrot, Francoise, Maes, Piet, Grzelak, Ludivine, Prot, Matthieu, Mougari, Said, Planchais, Cyril, Puech, Julien, Saliba, Madelina, Sahraoui, Riwan, Femy, Florent, Morel, Nathalie, Dufloo, Jeremy, Sanjuán, Rafael, Mouquet, Hugo, Andre, Emmanuel, Hocqueloux, Laurent, Simon-Loriere, Etienne, Veyer, David, Prazuck, Thierry, Péré, Hélène, and Schwartz, Olivier

Abstract

Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 lineages has led to the emergence of several new subvariants, including BA.2.75.2, BA.4.6. and BQ.1.1. The subvariant BQ.1.1 became predominant in many countries in December 2022. The subvariants carry an additional and often redundant set of mutations in the spike, likely responsible for increased transmissibility and immune evasion. Here, we established a viral amplification procedure to easily isolate Omicron strains. We examined their sensitivity to 6 therapeutic monoclonal antibodies (mAbs) and to 72 sera from Pfizer BNT162b2-vaccinated individuals, with or without BA.1/BA.2 or BA.5 breakthrough infection. Ronapreve (Casirivimab and Imdevimab) and Evusheld (Cilgavimab and Tixagevimab) lose antiviral efficacy against BA.2.75.2 and BQ.1.1, whereas Xevudy (Sotrovimab) remaine weakly active. BQ.1.1 is also resistant to Bebtelovimab. Neutralizing titers in triply vaccinated individuals are low to undetectable against BQ.1.1 and BA.2.75.2, 4 months after boosting. A BA.1/BA.2 breakthrough infection increases these titers, which remains about 18-fold lower against BA.2.75.2 and BQ.1.1, than against BA.1. Reciprocally, a BA.5 breakthrough infection increases more efficiently neutralization against BA.5 and BQ.1.1 than against BA.2.75.2. Thus, the evolution trajectory of novel Omicron subvariants facilitates their spread in immunized populations and raises concerns about the efficacy of most available mAbs.

Published
2023

22. Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

Author

Garcia, Magalie, Giraud, Valentin, Metais, Agathe, Cazenave-Roblot, Fance, Martellosio Anne-Marie Ronchetti, Jean-Philippe, Gabas, Thomas, Hadjadj, Naima, Salanoubat, Célia, Chabrol, Amélie, Housset, Pierre, Pardon, Agathe, Faucon, Anne-Laure, Caudwell, Valérie, Roland Liblau, Latifa Hanafi, Alric, Laurent, Pugnet, Grégory, Mourguet, Morgane, Bories, Eva, Bonnet, Delphine, Charpentier, Sandrine, Delobel, Pierre, Debard, Alexa, Beck, Colleen, Boumaza, Xavier, Fanny Lanternier, Stella Rousset, Delage, Claire, Pires, Elisabete Gomes, Cheminant, Morgane, Anthony Chauvin, Nathalie Chavarot, Véronique Delcey Simon Bessis, Xavier Eyer, Cresta, Mélanie, Pélagie Thibaut, Romain Gueneau, Nadal, Marine, Siguier, Martin, Bachir, Marwa, Valérie Pourcher, Christia Palacios, Melenotte, Cléa, Faycal, Antoine, Berot, Vincent, Brin, Cécile, Djebara, Siham, Zafilaza, Karen, Marot, Stéphane, Sayon, Sophie, Leducq, Vincent, Malet, Isabelle, Teyssou, Elisa, Karine Lacombe, Adélie Gothland, Aad, Yasmine Abi, Chiarabini, Thibault, Feliho, Raynald, Valin, Nadia, Brigant, Fabien, Boize, Julien, Thiébaud, Pierre-Clément, Moreau, Marie, Nathalie De Castro, Charlotte Billard, Liégeon, Geoffroy, Denis, Blandine, Molina, Jean-Michel, André Cabié, Lucia Etheve, Abel, Sylvie, Cabras, Ornella, Guitteaud, Karine, François Vincent Dubee, Sandrine Pierre, Ndiaye, Diama, Pehlivan, Jonathan, Phelippeau, Michael, Alexandre Duvignaud, Rafael Mahieu, Pistone, Thierry, Desclaux, Arnaud, Neau, Didier, Jean-François Faucher, Charles Cazanave, Festou, Benjamin, Dupuy-Grasset, Magali, Loustaud-Ratti, Véronique, Nathan Peiffer- Smadja, Delphine Chainier, Choquet, Christophe, Da Conceicao, Olivia, Thy, Michael, Collas, Lio, Godard, Cindy, Bouzid, Donia, Ing, Vittiaroat, Pereira, Laurent, Pavlowsky, Thomas, RavautAntoine Asquier-Khati, Camille, Boutoille, David, Chauveau, Marie, Deschanvres, Colin, Audrey Le Bot, François Raffi, Cailleaux, Marine, Benezit, François, Maillard, Anne, Hue, Benoit, François Coustilleres, Pierre Tattevin, Carvalho-Schneider, Claudia, Jamard, Simon, Petit, Laeticia, Natacha Mrozek, Karl Stefic, Theis, Clément, Vidal, Magali, Sauvat, Léo, Benjamin Lefèvre, Delphine Martineau, Baronnet, Guillaume, Florence Ader, Agnès Didier, Perpoint, Thomas, Conrad, Anne, Chabert, Paul, Aurélie Martin, Pierre Chauvelot, Loubet, Paul, Mazet, Julien, Larcher, Romaric, Mathilde Devaux Jérôme Frey, Didier Laureillard, Woerlen, Amos, Remillon, Aline, Absensur-Vuillaume, Laure, Albert Trinh-Duc, Pauline Bouquet, Philippe Petua, Patrick Rispal, Aurore Perrot, Julien Carillo, Delavigne, Karen, Cougoul, Pierre, Dion, Jérémie, Mathieu Blot, Odile Rauzy, Sixt, Thibault, Moretto, Florian, Charles, Carole, Sophie Circosta, Lionel Piroth, Leger, Lydia, Arulananthan, Arulvani, Lascoux, Carine, Valérie, Pascaline, Yazdan Yazdanpanah, Leia Becam, Petrov-Sanchez, Ventzislava, Diallo, Alpha, Le Mestre, Soizic, Le Meut Isabelle Goderel, Guillaume, Chau, Frédéric, Soltana, Brahim, Chane Tang, Jessica, Guedj, Jérémie, Caille, Yvanie, Bruel, Timothée, Vrignaud, Lou-Léna, Porrot, Françoise, Staropoli, Isabelle, Planas, Delphine, Guivel-Benhassine, Florence, Puech, Julien, Prot, Matthieu, Munier, Sandie, Bolland, William Henry, Soulié, Cathia, Lusivika-Nzinga, Clovis, Meledge, Marie-Laure, Dorival, Céline, Molino, Diana, Péré, Hélène, Yordanov, Youri, Simon-Lorière, Etienne, Veyer, David, Carrat, Fabrice, Schwartz, Olivier, Marcelin, Anne-Geneviève, and Martin-Blondel, Guillaume

Published
2023
Full Text
View/download PDF

23. Modelling the association between neutralizing antibody levels and SARS-CoV-2 viral dynamics : implications to define correlates of protection against infection

Author

Lingas, Guillaume, primary, Planas, Delphine, additional, Péré, Hélène, additional, Duffy, Darragh, additional, Staropoli, Isabelle, additional, Porrot, Françoise, additional, Guivel-Benhassine, Florence, additional, Chapuis, Nicolas, additional, Gobeaux, Camille, additional, Veyer, David, additional, Delaugerre, Constance, additional, Goff, Jérôme Le, additional, Getten, Prunelle, additional, Hadjadj, Jérôme, additional, Bellino, Adèle, additional, Parfait, Béatrice, additional, Treluyer, Jean-Marc, additional, Schwartz, Olivier, additional, Guedj, Jérémie, additional, Kernéis, Solen, additional, and Terrier, Benjamin, additional

Published
2023
Full Text
View/download PDF

24. Beta-Variant Recombinant Booster Vaccine Elicits Broad Cross-Reactive Neutralization of SARS-CoV-2 Including Omicron Variants

Author

Planas, Delphine, primary, Peng, Lin, additional, Zheng, Lingyi, additional, Guivel-Benhassine, Florence, additional, Staropoli, Isabelle, additional, Porrot, Françoise, additional, Bruel, Timothée, additional, Bhiman, Jinal N., additional, Bonaparte, Matthew, additional, Savarino, Stephen, additional, Chicz, Roman M., additional, de Bruyn, Guy, additional, Moore, Penny L., additional, Schwartz, Olivier, additional, and Sridhar, Saranya, additional

Published
2023
Full Text
View/download PDF

25. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection

Author

Planas, Delphine, primary, Staropoli, Isabelle, additional, Porot, Françoise, additional, Guivel-Benhassine, Florence, additional, Handala, Lynda, additional, Prot, Matthieu, additional, Bolland, William-Henry, additional, Puech, Julien, additional, Péré, Hélène, additional, Veyer, David, additional, Sève, Aymeric, additional, Simon-Lorière, Etienne, additional, Bruel, Timothée, additional, Prazuck, Thierry, additional, Stefic, Karl, additional, Hocqueloux, Laurent, additional, and Schwartz, Olivier, additional

Published
2022
Full Text
View/download PDF

26. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies

Author

Bruel, Timothée, primary, Stéfic, Karl, additional, Nguyen, Yann, additional, Toniutti, Donatella, additional, Staropoli, Isabelle, additional, Porrot, Françoise, additional, Guivel-Benhassine, Florence, additional, Bolland, William-Henry, additional, Planas, Delphine, additional, Hadjadj, Jérôme, additional, Handala, Lynda, additional, Planchais, Cyril, additional, Prot, Matthieu, additional, Simon-Lorière, Etienne, additional, André, Emmanuel, additional, Baele, Guy, additional, Cuypers, Lize, additional, Mouthon, Luc, additional, Mouquet, Hugo, additional, Buchrieser, Julian, additional, Sève, Aymeric, additional, Prazuck, Thierry, additional, Maes, Piet, additional, Terrier, Benjamin, additional, Hocqueloux, Laurent, additional, and Schwartz, Olivier, additional

Published
2022
Full Text
View/download PDF

27. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies

Author

Planas, Delphine, primary, Bruel, Timothée, additional, Staropoli, Isabelle, additional, Guivel-Benhassine, Florence, additional, Porrot, Françoise, additional, Maes, Piet, additional, Grzelak, Ludivine, additional, Prot, Matthieu, additional, Mougari, Said, additional, Planchais, Cyril, additional, Puech, Julien, additional, Saliba, Madelina, additional, Sahraoui, Riwan, additional, Fémy, Florent, additional, Morel, Nathalie, additional, Dufloo, Jérémy, additional, Sanjuán, Rafael, additional, Mouquet, Hugo, additional, André, Emmanuel, additional, Hocqueloux, Laurent, additional, Simon-Loriere, Etienne, additional, Veyer, David, additional, Prazuck, Thierry, additional, Péré, Hélène, additional, and Schwartz, Olivier, additional

Published
2022
Full Text
View/download PDF

28. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

Author

Planchais, Cyril, Fernández, Ignacio, Bruel, Timothée, de Melo, Guilherme, Prot, Matthieu, Beretta, Maxime, Guardado-Calvo, Pablo, Dufloo, Jérémy, Molinos-Albert, Luis, Backovic, Marija, Chiaravalli, Jeanne, Giraud, Emilie, Vesin, Benjamin, Conquet, Laurine, Grzelak, Ludivine, Planas, Delphine, Staropoli, Isabelle, Guivel-Benhassine, Florence, Hieu, Thierry, Boullé, Mikaël, Cervantes-Gonzalez, Minerva, Ungeheuer, Marie-Noëlle, Charneau, Pierre, van der Werf, Sylvie, Agou, Fabrice, Bartoli, Marie, Diallo, Alpha, Le Mestre, Soizic, Paul, Christelle, Petrov-Sanchez, Ventzislava, Yazdanpanah, Yazdan, Ficko, Cécile, Chirouze, Catherine, Andrejak, Claire, Malvy, Denis, Goehringer, François, Rossignol, Patrick, Gigante, Tristan, Gilg, Morgane, Rossignol, Bénédicte, Etienne, Manuel, Beluze, Marine, Bachelet, Delphine, Bhavsar, Krishna, Bouadma, Lila, Chair, Anissa, Charpentier, Charlotte, Chenard, Léo, Couffignal, Camille, Debray, Marie-Pierre, Descamps, Diane, Duval, Xavier, Eloy, Philippine, Esposito-Farese, Marina, Florence, Aline-Marie, Ghosn, Jade, Hoffmann, Isabelle, Kafif, Ouifiya, Khalil, Antoine, Lafhej, Nadhem, Laouénan, Cédric, Laribi, Samira, Le, Minh, Le Hingrat, Quentin, Letrou, Sophie, Mentré, France, Peytavin, Gilles, Piquard, Valentine, Roy, Carine, Schneider, Marion, Su, Richa, Tardivon, Coralie, Timsit, Jean-François, Tubiana, Sarah, Visseaux, Benoît, Deplanque, Dominique, Hulot, Jean-Sébastien, Diehl, Jean-Luc, Picone, Olivier, Angoulvant, François, Abrous, Amal, Couffin-Cadiergues, Sandrine, da Silva, Fernanda, Esperou, Hélène, Houas, Ikram, Jaafoura, Salma, Papadopoulos, Aurélie, Gaymard, Alexandre, Lina, Bruno, Rosa-Calatrava, Manuel, Dorival, Céline, Guedj, Jérémie, Lingas, Guillaume, Neant, Nadège, Abel, Laurent, Manda, Victoria, Behillil, Sylvie, Enouf, Vincent, Levy, Yves, Wiedemann, Aurélie, Arowas, Laurence, Perlaza, Blanca, Perrin de Facci, Louise, Chaouche, Sophie, Sangari, Linda, Renaudat, Charlotte, Fernandes Pellerin, Sandrine, van Platen, Cassandre, Jolly, Nathalie, Kuhmel, Lucie, Garaud, Valentine, Rafanoson, Hantaniaina, Gardais, Soazic, de Parseval, Nathalie, Dugast, Claire, Jannet, Caroline, Ropars, Sandrine, Momboisse, Fanny, Porteret, Isabelle, Cailleau, Isabelle, Hoen, Bruno, Tondeur, Laura, Besombes, Camille, Fontanet, Arnaud, Dimitrov, Jordan, Simon-Lorière, Etienne, Bourhy, Hervé, Montagutelli, Xavier, Rey, Félix, Schwartz, Olivier, Mouquet, Hugo, Covid Cohort Study Group, French, Study Group, Corser, Immunologie humorale - Humoral Immunology, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Virologie Structurale - Structural Virology, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Virus et Immunité - Virus and immunity (CNRS-UMR3569), Vaccine Research Institute [Créteil, France] (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Lyssavirus, épidémiologie et neuropathologie - Lyssavirus Epidemiology and Neuropathology, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Génomique évolutive des virus à ARN - Evolutionary genomics of RNA viruses, Université Paris Cité (UPCité), École Doctorale Bio Sorbonne Paris Cité [Paris] (ED562 - BioSPC), Université Sorbonne Paris Cité (USPC)-Université Paris Cité (UPCité), Criblage chémogénomique et biologique (Plateforme) - Chemogenomic and Biological Screening Platform (PF-CCB), Laboratoire commun Pasteur-TheraVectys, Institut Pasteur [Paris] (IP)-TheraVectys-Université Paris Cité (UPCité), Génétique de la souris - Mouse Genetics, Génétique fonctionnelle des Maladies infectieuses - Functional Genetics of Infectious Diseases, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Investigation Clinique et d’Accès aux Ressources Biologiques (Plate-forme) - Clinical Investigation and Access to BioResources (ICAReB), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), FundingFunder(s): Institut PasteurFunder(s): French Government’s Investissements d’Avenir program Award Id(s): ANR-11-EQPX-0008Funder(s): Institut national de la santé et de la recherche médicaleFunder(s): REsearch & ACtion emergING infectious diseases (REACTing) consortiumFunder(s): Ministry of Health and Social AffairsFunder(s): Ministry of Higher Education and ResearchFunder(s): Agence Nationale de la Recherche Award Id(s): #20RR028-00Funder(s): European Commission Award Id(s): #101003589Funder(s): Fondation de France Award Id(s): #00106077Funder(s): Agence Nationale de Recherches sur le Sida et les Hépatites ViralesFunder(s): Programme hospitalier de recherche clinique Award Id(s): 20-0424, ANR-11-EQPX-0008,CACSICE,Centre d'analyse de systèmes complexes dans les environnements complexes(2011), ANR-21-CO14-0007,CoronaMito,Conséquences de l'infection par le SRAS-CoV-2 sur la fonction mitochondriale(2021), European Project: 101003589, H2020-SC1-PHE-CORONAVIRUS-2020,RECOVER(2020), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Virologie Structurale, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Virus et Immunité - Virus and immunity, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Vaccine Research Institute (VRI), Processus infectieux à Trypanosomatidés - Trypanosomatids Infectious Processes, Institut Pasteur [Paris]-Université Paris Cité (UPCité), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris], Interactions Virus-Insectes - Insect-Virus Interactions (IVI), and Institut Pasteur [Paris]-TheraVectys-Université Paris Cité (UPCité)

Subjects
[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, SARS-CoV-2, Immunoglobulin G, Spike Glycoprotein, Coronavirus, Immunology, Animals, COVID-19, Humans, Immunology and Allergy, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Antibodies, Viral, Antibodies, Neutralizing, Immunoglobulin A
Abstract

International audience; Memory B-cell and antibody responses to the SARS-CoV-2 spike protein contribute to long-term immune protection against severe COVID-19, which can also be prevented by antibody-based interventions. Here, wide SARS-CoV-2 immunoprofiling in Wuhan COVID-19 convalescents combining serological, cellular, and monoclonal antibody explorations revealed humoral immunity coordination. Detailed characterization of a hundred SARS-CoV-2 spike memory B-cell monoclonal antibodies uncovered diversity in their repertoire and antiviral functions. The latter were influenced by the targeted spike region with strong Fc-dependent effectors to the S2 subunit and potent neutralizers to the receptor-binding domain. Amongst those, Cv2.1169 and Cv2.3194 antibodies cross-neutralized SARS-CoV-2 variants of concern, including Omicron BA.1 and BA.2. Cv2.1169, isolated from a mucosa-derived IgA memory B cell demonstrated potency boost as IgA dimers and therapeutic efficacy as IgG antibodies in animal models. Structural data provided mechanistic clues to Cv2.1169 potency and breadth. Thus, potent broadly neutralizing IgA antibodies elicited in mucosal tissues can stem SARS-CoV-2 infection, and Cv2.1169 and Cv2.3194 are prime candidates for COVID-19 prevention and treatment.

Published
2022

29. Supplementary Information and Source Data for Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells

Author

Dufloo, Jeremy, Planchais, Cyril, Frémont, Stéphane, Lorin, Valérie, Guivel-Benhassine, Florence, Stefic, Karl, Casartelli, Nicoletta, Echard, Arnaud, Roingeard, Philippe, Mouquet, Hugo, Schwartz, Olivier, Bruel, Timothee, Dufloo, Jeremy, Planchais, Cyril, Frémont, Stéphane, Lorin, Valérie, Guivel-Benhassine, Florence, Stefic, Karl, Casartelli, Nicoletta, Echard, Arnaud, Roingeard, Philippe, Mouquet, Hugo, Schwartz, Olivier, and Bruel, Timothee

Published
2022

30. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells

Author

Institut Pasteur, Agence Nationale de la Recherche (France), Ministére de l'Education Nationale de la Recherche et de la Technologie (France), Université de Tours, Dufloo, Jeremy, Planchais, Cyril, Frémont, Stéphane, Lorin, Valérie, Guivel-Benhassine, Florence, Stefic, Karl, Casartelli, Nicoletta, Echard, Arnaud, Roingeard, Philippe, Mouquet, Hugo, Schwartz, Olivier, Bruel, Timothee, Institut Pasteur, Agence Nationale de la Recherche (France), Ministére de l'Education Nationale de la Recherche et de la Technologie (France), Université de Tours, Dufloo, Jeremy, Planchais, Cyril, Frémont, Stéphane, Lorin, Valérie, Guivel-Benhassine, Florence, Stefic, Karl, Casartelli, Nicoletta, Echard, Arnaud, Roingeard, Philippe, Mouquet, Hugo, Schwartz, Olivier, and Bruel, Timothee

Abstract

Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) are promising molecules for therapeutic or prophylactic interventions. Beyond neutralization, bNAbs exert Fc-dependent functions including antibody-dependent cellular cytotoxicity and activation of the complement. Here, we show that a subset of bNAbs targeting the CD4 binding site and the V1/V2 or V3 loops inhibit viral release from infected cells. We combined immunofluorescence, scanning electron microscopy, transmission electron microscopy and immunogold staining to reveal that some bNAbs form large aggregates of virions at the surface of infected cells. This activity correlates with the capacity of bNAbs to bind to Env at the cell surface and to neutralize cell-free viral particles. We further show that antibody bivalency is required for viral retention, and that aggregated virions are neutralized. We have thus identified an additional antiviral activity of bNAbs, which block HIV-1 release by tethering viral particles at the surface of infected cells.

Published
2022

31. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies

Author

Bruel, Timothee [0000-0002-3952-4261], Grzelak, Ludivine [0000-0002-1298-7565], Sanjuán, Rafael [0000-0002-1844-545X], Simon-Loriere, Etienne [0000-0001-8420-7743], Schwartz, Olivier [0000-0002-0729-1475], Planas, Delphine, Bruel, Timothee, Staropoli, Isabelle, Guivel-Benhassine, Florence, Porrot, Francoise, Maes, Piet, Grzelak, Ludivine, Prot, Matthieu, Mougari, Said, Planchais, Cyril, Puech, Julien, Saliba, Madelina, Sahraoui, Riwan, Femy, Florent, Morel, Nathalie, Dufloo, Jeremy, Sanjuán, Rafael, Mouquet, Hugo, Andre, Emmanuel, Hocqueloux, Laurent, Simon-Loriere, Etienne, Veyer, David, Prazuck, Thierry, Péré, Hélène, Schwartz, Olivier, Bruel, Timothee [0000-0002-3952-4261], Grzelak, Ludivine [0000-0002-1298-7565], Sanjuán, Rafael [0000-0002-1844-545X], Simon-Loriere, Etienne [0000-0001-8420-7743], Schwartz, Olivier [0000-0002-0729-1475], Planas, Delphine, Bruel, Timothee, Staropoli, Isabelle, Guivel-Benhassine, Florence, Porrot, Francoise, Maes, Piet, Grzelak, Ludivine, Prot, Matthieu, Mougari, Said, Planchais, Cyril, Puech, Julien, Saliba, Madelina, Sahraoui, Riwan, Femy, Florent, Morel, Nathalie, Dufloo, Jeremy, Sanjuán, Rafael, Mouquet, Hugo, Andre, Emmanuel, Hocqueloux, Laurent, Simon-Loriere, Etienne, Veyer, David, Prazuck, Thierry, Péré, Hélène, and Schwartz, Olivier

Abstract

Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 lineages has led to the emergence of several new subvariants, including BA.2.75.2, BA.4.6. and BQ.1.1. The subvariants BA.2.75.2 and BQ.1.1 are expected to become predominant in many countries in November 2022. They carry an additional and often redundant set of mutations in the spike, likely responsible for increased transmissibility and immune evasion. Here, we established a viral amplification procedure to easily isolate Omicron strains. We examined their sensitivity to 6 therapeutic monoclonal antibodies (mAbs) and to 72 sera from Pfizer BNT162b2-vaccinated individuals, with or without BA.1/BA.2 or BA.5 breakthrough infection. Ronapreve (Casirivimab and Imdevimab) and Evusheld (Cilgavimab and Tixagevimab) lost any antiviral efficacy against BA.2.75.2 and BQ.1.1, whereas Xevudy (Sotrovimab) remained weakly active. BQ.1.1 was also resistant to Bebtelovimab. Neutralizing titers in triply vaccinated individuals were low to undetectable against BQ.1.1 and BA.2.75.2, 4 months after boosting. A BA.1/BA.2 breakthrough infection increased these titers, which remained about 18-fold lower against BA.2.75.2 and BQ.1.1, than against BA.1. Reciprocally, a BA.5 breakthrough infection increased more efficiently neutralization against BA.5 and BQ.1.1 than against BA.2.75.2. Thus, the evolution trajectory of novel Omicron subvariants facilitated their spread in immunized populations and raises concerns about the efficacy of most currently available mAbs.

Published
2022

33. SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine

Author

Bruel, Timothée, primary, Pinaud, Laurie, additional, Tondeur, Laura, additional, Planas, Delphine, additional, Staropoli, Isabelle, additional, Porrot, Françoise, additional, Guivel-Benhassine, Florence, additional, Attia, Mikaël, additional, Pelleau, Stéphane, additional, Woudenberg, Tom, additional, Duru, Cécile, additional, Koffi, Aymar Davy, additional, Castelain, Sandrine, additional, Fernandes-Pellerin, Sandrine, additional, Jolly, Nathalie, additional, De Facci, Louise Perrin, additional, Roux, Emmanuel, additional, Ungeheuer, Marie-Noëlle, additional, Van Der Werf, Sylvie, additional, White, Michael, additional, Schwartz, Olivier, additional, and Fontanet, Arnaud, additional

Published
2022
Full Text
View/download PDF

34. Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies

Author

Bruel, Timothée, primary, Hadjadj, Jérôme, additional, Maes, Piet, additional, Planas, Delphine, additional, Seve, Aymeric, additional, Staropoli, Isabelle, additional, Guivel-Benhassine, Florence, additional, Porrot, Françoise, additional, Bolland, William-Henry, additional, Nguyen, Yann, additional, Casadevall, Marion, additional, Charre, Caroline, additional, Péré, Hélène, additional, Veyer, David, additional, Prot, Matthieu, additional, Baidaliuk, Artem, additional, Cuypers, Lize, additional, Planchais, Cyril, additional, Mouquet, Hugo, additional, Baele, Guy, additional, Mouthon, Luc, additional, Hocqueloux, Laurent, additional, Simon-Loriere, Etienne, additional, André, Emmanuel, additional, Terrier, Benjamin, additional, Prazuck, Thierry, additional, and Schwartz, Olivier, additional

Published
2022
Full Text
View/download PDF

35. Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller

Author

Lorin, Valérie, primary, Fernández, Ignacio, additional, Masse-Ranson, Guillemette, additional, Bouvin-Pley, Mélanie, additional, Molinos-Albert, Luis M., additional, Planchais, Cyril, additional, Hieu, Thierry, additional, Péhau-Arnaudet, Gérard, additional, Hrebík, Dominik, additional, Girelli-Zubani, Giulia, additional, Fiquet, Oriane, additional, Guivel-Benhassine, Florence, additional, Sanders, Rogier W., additional, Walker, Bruce D., additional, Schwartz, Olivier, additional, Scheid, Johannes F., additional, Dimitrov, Jordan D., additional, Plevka, Pavel, additional, Braibant, Martine, additional, Seaman, Michael S., additional, Bontems, François, additional, Di Santo, James P., additional, Rey, Félix A., additional, and Mouquet, Hugo, additional

Published
2022
Full Text
View/download PDF

36. Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

Author

Saunders, Nell, primary, Planas, Delphine, additional, Bolland, William, additional, Rodriguez, Christophe, additional, Fourati, Slim, additional, Buchrieser, Julian, additional, Planchais, Cyril, additional, Prot, Matthieu, additional, Staropoli, Isabelle, additional, Guivel-Benhassine, Florence, additional, Porrot, Françoise, additional, Veyer, David, additional, Péré, Hélène, additional, Robillard, Nicolas, additional, Saliba, Madelina, additional, Baidaliuk, Artem, additional, Seve, Aymeric, additional, Hocqueloux, Laurent, additional, Prazuck, Thierry, additional, Mouquet, Hugo, additional, Simon-Lorière, Etienne, additional, Bruel, Timothée, additional, Pawlotsky, Jean-Michel, additional, and Schwartz, Olivier, additional

Published
2022
Full Text
View/download PDF

37. Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study

Author

Monel, Blandine, Planas, Delphine, Grzelak, Ludivine, Smith, Nikaïa, Robillard, Nicolas, Staropoli, Isabelle, Goncalves, Pedro, Porrot, Françoise, Guivel-Benhassine, Florence, Guinet, Nathalie Demory, Rodary, Julien, Puech, Julien, Euzen, Victor, Bélec, Laurent, Orvoen, Galdric, Nunes, Léa, Moulin, Véronique, Fourgeaud, Jacques, Wack, Maxime, Imbeaud, Sandrine, Campagne, Pascal, Duffy, Darragh, Di Santo, James, Bruel, Timothée, Péré, Hélène, Veyer, David, Schwartz, Olivier, Virus et Immunité - Virus and immunity (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Vaccine Research Institute [Créteil, France] (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Paris Cité (UPCité), Immunologie Translationnelle - Translational Immunology lab, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Immunité Innée - Innate Immunity, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Vaugirard-Gabriel Pallez, Hôpital Corentin Celton [Issy-les-Moulineaux], Laboratoire de Virologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Work in OS lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2 and IDISCOVR, Fondation pour la Recherche Médicale. DP is supported by the Vaccine Research Institute. LG is supported by the French Ministry of Higher Education, Research and Innovation. DD and JDS are funded by the ANR-20-COVI-0053 grant., We thank Maaran Michael Rajah, Nicoletta Casartelli, Michael White and Jeremy Dufloo for discussion and critical reading of the manuscript. We thank AGEPS, Assistance Publique - Hôpitaux de Paris, for providing the RDTs. We thank the patients who participated in the study, the clinical staff involved in their management, Théo Hirsch for stimulating discussions. We thank members of the Virus and Immunity Unit for discussion and help, Nathalie Aulner and the UtechS Photonic BioImaging (UPBI) core facility (Institut Pasteur), a member of the France BioImaging network, for image acquisition and analysis, and Cyril Planchais & Hugo Mouquet for the kind gift of mAb48., ANR-10-LABX-0077,VRI,Initiative for the creation of a Vaccine Research Institute(2010), ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), ANR-20-COVI-0059,PROTEO-SARS-CoV-2,Protéomique du SARS-CoV-2(2020), ANR-20-COVI-0053,CoVarImm,Variation de la réponse immune systémique et muqueuse pendant l'infection par le SRAS-CoV-2 et la convalescence(2020), Virus et Immunité - Virus and immunity, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Vaccine Research Institute (VRI), Institut Pasteur [Paris]-Université Paris Cité (UPCité), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), École pratique des hautes études (EPHE), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Université de Paris (UP), Institut Pasteur [Paris], Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP)

Subjects
Adult, Male, Nasal swabs, Medicine (General), variants, Research paper, SARS-CoV-2, COVID-19, Middle Aged, Antibodies, Viral, Immunoglobulin A, infectious particles, R5-920, Immunoglobulin G, Nasopharynx, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Medicine, Cytokines, Humans, Female, Aged, Retrospective Studies
Abstract

Background: The dynamics of SARS-CoV-2 alpha variant shedding and immune responses at the nasal mucosa remain poorly characterised. Methods: We measured infectious viral release, antibodies and cytokines in 426 PCR+ nasopharyngeal swabs from individuals harboring non-alpha or alpha variants. Findings: With both lineages, viral titers were variable, ranging from 0 to >106 infectious units. Rapid antigenic diagnostic tests were positive in 94% of samples with infectious virus. 68 % of individuals carried infectious virus within two days after onset of symptoms. This proportion decreased overtime. Viable virus was detected up to 14 days. Samples containing anti-spike IgG or IgA did not generally harbor infectious virus. Ct values were slightly but not significantly lower with alpha. This variant was characterized by a fast decrease of infectivity overtime and a marked release of 13 cytokines (including IFN-b, IP-10 and IL-10). Interpretation: The alpha variant displays modified viral decay and cytokine profiles at the nasopharyngeal mucosae during symptomatic infection. Funding: This retrospective study has been funded by Institut Pasteur, ANRS, Vaccine Research Institute, Labex IBEID, ANR/FRM and IDISCOVR, Fondation pour la Recherche Médicale.

Published
2021

38. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Author

Planas, Delphine, primary, Saunders, Nell, additional, Maes, Piet, additional, Guivel-Benhassine, Florence, additional, Planchais, Cyril, additional, Buchrieser, Julian, additional, Bolland, William-Henry, additional, Porrot, Françoise, additional, Staropoli, Isabelle, additional, Lemoine, Frederic, additional, Péré, Hélène, additional, Veyer, David, additional, Puech, Julien, additional, Rodary, Julien, additional, Baele, Guy, additional, Dellicour, Simon, additional, Raymenants, Joren, additional, Gorissen, Sarah, additional, Geenen, Caspar, additional, Vanmechelen, Bert, additional, Wawina-Bokalanga, Tony, additional, Martí-Carreras, Joan, additional, Cuypers, Lize, additional, Sève, Aymeric, additional, Hocqueloux, Laurent, additional, Prazuck, Thierry, additional, Rey, Félix A., additional, Simon-Loriere, Etienne, additional, Bruel, Timothée, additional, Mouquet, Hugo, additional, André, Emmanuel, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

39. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization

Author

Planas, Delphine, primary, Saunders, Nell, additional, Maes, Piet, additional, Guivel-Benhassine, Florence, additional, Planchais, Cyril, additional, Buchrieser, Julian, additional, Bolland, William-Henry, additional, Porrot, Françoise, additional, Staropoli, Isabelle, additional, Lemoine, Frederic, additional, Péré, Hélène, additional, Veyer, David, additional, Puech, Julien, additional, Rodary, Julien, additional, Baela, Guy, additional, Dellicour, Simon, additional, Raymenants, Joren, additional, Gorissen, Sarah, additional, Geenen, Caspar, additional, Vanmechelen, Bert, additional, Wawina-Bokalanga, Tony, additional, Martí-Carrerasi, Joan, additional, Cuypers, Lize, additional, Sève, Aymeric, additional, Hocqueloux, Laurent, additional, Prazuck, Thierry, additional, Rey, Félix, additional, Simon-Lorrière, Etienne, additional, Bruel, Timothée, additional, Mouquet, Hugo, additional, André, Emmanuel, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

40. SARS‐CoV‐2 Alpha, Beta, and Delta variants display enhanced Spike‐mediated syncytia formation

Author

Rajah, Maaran Michael, primary, Hubert, Mathieu, additional, Bishop, Elodie, additional, Saunders, Nell, additional, Robinot, Remy, additional, Grzelak, Ludivine, additional, Planas, Delphine, additional, Dufloo, Jérémy, additional, Gellenoncourt, Stacy, additional, Bongers, Alice, additional, Zivaljic, Marija, additional, Planchais, Cyril, additional, Guivel‐Benhassine, Florence, additional, Porrot, Françoise, additional, Mouquet, Hugo, additional, Chakrabarti, Lisa A, additional, Buchrieser, Julian, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

41. A screening pipeline identifies a broad-spectrum inhibitor of bacterial AB toxins with cross protection against influenza A virus H1N1 and SARS-CoV-2

Author

Wu, Yu, primary, Mahtal, Nassim, additional, Swistak, Léa, additional, Sagadiev, Sara, additional, Acharya, Mridu, additional, Demeret, Caroline, additional, van der Werf, Sylvie, additional, Guivel-Benhassine, Florence, additional, Schwartz, Olivier, additional, Petracchini, Serena, additional, Mettouchi, Amel, additional, Paillares, Eléa, additional, Caramelle, Lucie, additional, Couvineau, Pierre, additional, Thai, Robert, additional, Barbe, Peggy, additional, Keck, Mathilde, additional, Brodin, Priscille, additional, Machelart, Arnaud, additional, Sencio, Valentin, additional, Trottein, François, additional, Sachse, Martin, additional, Chicanne, Gaëtan, additional, Payrastre, Bernard, additional, Ville, Florian, additional, Kreis, Victor, additional, Popoff, Michel-Robert, additional, Johannes, Ludger, additional, Cintrat, Jean-Christophe, additional, Barbier, Julien, additional, Gillet, Daniel, additional, and Lemichez, Emmanuel, additional

Published
2021
Full Text
View/download PDF

42. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Author

Planas, Delphine, Saunders, Nell, Maes, Piet, Guivel-Benhassine, Florence, Planchais, Cyril, Buchrieser, Julian, Bolland, William Henry, Porrot, Françoise, Staropoli, Isabelle, Lemoine, Frédéric, Péré, Hélène, Veyer, David, Puech, Julien, Rodary, Julien, Baele, Guy, Dellicour, Simon, Raymenants, Joren, Gorissen, Sarah, Geenen, Caspar, Vanmechelen, Bert, Wawina-Bokalanga, Tony, Martí-Carreras, Joan, Cuypers, Lize, Sève, Aymeric, Hocqueloux, Laurent, Prazuck, Thierry, Rey, Felix, Simon-Loriere, Etienne, Bruel, Timothée, Mouquet, Hugo, André, Emmanuel, Schwartz, Olivier, Planas, Delphine, Saunders, Nell, Maes, Piet, Guivel-Benhassine, Florence, Planchais, Cyril, Buchrieser, Julian, Bolland, William Henry, Porrot, Françoise, Staropoli, Isabelle, Lemoine, Frédéric, Péré, Hélène, Veyer, David, Puech, Julien, Rodary, Julien, Baele, Guy, Dellicour, Simon, Raymenants, Joren, Gorissen, Sarah, Geenen, Caspar, Vanmechelen, Bert, Wawina-Bokalanga, Tony, Martí-Carreras, Joan, Cuypers, Lize, Sève, Aymeric, Hocqueloux, Laurent, Prazuck, Thierry, Rey, Felix, Simon-Loriere, Etienne, Bruel, Timothée, Mouquet, Hugo, André, Emmanuel, and Schwartz, Olivier

Abstract

The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and South Africa1–3. It has since then spread to many countries and is expected to rapidly become dominant worldwide. The lineage is characterized by the presence of about 32 mutations in the spike, located mostly in the N-terminal domain (NTD) and the receptor binding domain (RBD), which may enhance viral fitness and allow antibody evasion. Here, we isolated an infectious Omicron virus in Belgium, from a traveller returning from Egypt. We examined its sensitivity to 9 monoclonal antibodies (mAbs) clinically approved or in development4, and to antibodies present in 115 sera from COVID-19 vaccine recipients or convalescent individuals. Omicron was totally or partially resistant to neutralization by all mAbs tested. Sera from Pfizer or AstraZeneca vaccine recipients, sampled 5 months after complete vaccination, barely inhibited Omicron. Sera from COVID-19 convalescent patients collected 6 or 12 months post symptoms displayed low or no neutralizing activity against Omicron. Administration of a booster Pfizer dose as well as vaccination of previously infected individuals generated an anti-Omicron neutralizing response, with titers 6 to 23 fold lower against Omicron than against Delta. Thus, Omicron escapes most therapeutic monoclonal antibodies and to a large extent vaccine-elicited antibodies. Omicron remains however neutralized by antibodies generated by a booster vaccine dose., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2021

43. Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals

Author

Planas, Delphine, primary, Veyer, David, additional, Baidaliuk, Artem, additional, Staropoli, Isabelle, additional, Guivel-Benhassine, Florence, additional, Rajah, Maaran Michael, additional, Planchais, Cyril, additional, Porrot, Françoise, additional, Robillard, Nicolas, additional, Puech, Julien, additional, Prot, Matthieu, additional, Gallais, Floriane, additional, Gantner, Pierre, additional, Velay, Aurélie, additional, Le Guen, Julien, additional, Kassis-Chikhani, Najibi, additional, Edriss, Dhiaeddine, additional, Belec, Laurent, additional, Seve, Aymeric, additional, Péré, Hélène, additional, Courtellemont, Laura, additional, Hocqueloux, Laurent, additional, Fafi-Kremer, Samira, additional, Prazuck, Thierry, additional, Mouquet, Hugo, additional, Bruel, Timothée, additional, Simon-Lorière, Etienne, additional, Rey, Felix A., additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

44. Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-B.1.1.7 or B.1.1.7 SARS-CoV-2 variants

Author

Monel, Blandine, primary, Planas, Delphine, additional, Grzelak, Ludivine, additional, Smith, Nikaïa, additional, Robillard, Nicolas, additional, Staropoli, Isabelle, additional, Goncalves, Pedro, additional, Porrot, Françoise, additional, Guivel-Benhassine, Florence, additional, Guinet, Nathalie Demory, additional, Rodary, Julien, additional, Puech, Julien, additional, Euzen, Victor, additional, Bélec, Laurent, additional, Orvoen, Galdric, additional, Nunes, Léa, additional, Moulin, Véronique, additional, Fourgeaud, Jacques, additional, Wack, Maxime, additional, Imbeaud, Sandrine, additional, Campagne, Pascal, additional, Duffy, Darragh, additional, Di Santo, James P., additional, Bruel, Timothée, additional, Péré, Hélène, additional, Veyer, David, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

45. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Author

Planas, Delphine, primary, Bruel, Timothée, additional, Grzelak, Ludivine, additional, Guivel-Benhassine, Florence, additional, Staropoli, Isabelle, additional, Porrot, Françoise, additional, Planchais, Cyril, additional, Buchrieser, Julian, additional, Rajah, Maaran Michael, additional, Bishop, Elodie, additional, Albert, Mélanie, additional, Donati, Flora, additional, Behillil, Sylvie, additional, Enouf, Vincent, additional, Maquart, Marianne, additional, Gonzalez, Maria, additional, De Sèze, Jérôme, additional, Péré, Hélène, additional, Veyer, David, additional, Sève, Aymeric, additional, Simon-Lorière, Etienne, additional, Fafi-Kremer, Samira, additional, Stefic, Karl, additional, Mouquet, Hugo, additional, Hocqueloux, Laurent, additional, van der Werf, Sylvie, additional, Prazuck, Thierry, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

46. Syncytia formation by SARS‐CoV‐2‐infected cells

Author

Buchrieser, Julian, primary, Dufloo, Jérémy, additional, Hubert, Mathieu, additional, Monel, Blandine, additional, Planas, Delphine, additional, Rajah, Maaran Michael, additional, Planchais, Cyril, additional, Porrot, Françoise, additional, Guivel‐Benhassine, Florence, additional, Van der Werf, Sylvie, additional, Casartelli, Nicoletta, additional, Mouquet, Hugo, additional, Bruel, Timothée, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

47. Syncytia formation by SARS‐CoV‐2‐infected cells

Author

Buchrieser, Julian, primary, Dufloo, Jérémy, additional, Hubert, Mathieu, additional, Monel, Blandine, additional, Planas, Delphine, additional, Rajah, Maaran Michael, additional, Planchais, Cyril, additional, Porrot, Françoise, additional, Guivel‐Benhassine, Florence, additional, Van der Werf, Sylvie, additional, Casartelli, Nicoletta, additional, Mouquet, Hugo, additional, Bruel, Timothée, additional, and Schwartz, Olivier, additional

Published
2020
Full Text
View/download PDF

48. A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

Author

Grzelak, Ludivine, primary, Temmam, Sarah, additional, Planchais, Cyril, additional, Demeret, Caroline, additional, Tondeur, Laura, additional, Huon, Christèle, additional, Guivel-Benhassine, Florence, additional, Staropoli, Isabelle, additional, Chazal, Maxime, additional, Dufloo, Jeremy, additional, Planas, Delphine, additional, Buchrieser, Julian, additional, Rajah, Maaran Michael, additional, Robinot, Remy, additional, Porrot, Françoise, additional, Albert, Mélanie, additional, Chen, Kuang-Yu, additional, Crescenzo-Chaigne, Bernadette, additional, Donati, Flora, additional, Anna, François, additional, Souque, Philippe, additional, Gransagne, Marion, additional, Bellalou, Jacques, additional, Nowakowski, Mireille, additional, Backovic, Marija, additional, Bouadma, Lila, additional, Le Fevre, Lucie, additional, Le Hingrat, Quentin, additional, Descamps, Diane, additional, Pourbaix, Annabelle, additional, Laouénan, Cédric, additional, Ghosn, Jade, additional, Yazdanpanah, Yazdan, additional, Besombes, Camille, additional, Jolly, Nathalie, additional, Pellerin-Fernandes, Sandrine, additional, Cheny, Olivia, additional, Ungeheuer, Marie-Noëlle, additional, Mellon, Guillaume, additional, Morel, Pascal, additional, Rolland, Simon, additional, Rey, Felix A., additional, Behillil, Sylvie, additional, Enouf, Vincent, additional, Lemaitre, Audrey, additional, Créach, Marie-Aude, additional, Petres, Stephane, additional, Escriou, Nicolas, additional, Charneau, Pierre, additional, Fontanet, Arnaud, additional, Hoen, Bruno, additional, Bruel, Timothée, additional, Eloit, Marc, additional, Mouquet, Hugo, additional, Schwartz, Olivier, additional, and van der Werf, Sylvie, additional

Published
2020
Full Text
View/download PDF

49. SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors

Author

Grzelak, Ludivine, primary, Temmam, Sarah, additional, Planchais, Cyril, additional, Demeret, Caroline, additional, Huon, Christèle, additional, Guivel-Benhassine, Florence, additional, Staropoli, Isabelle, additional, Chazal, Maxime, additional, Dufloo, Jeremy, additional, Planas, Delphine, additional, Buchrieser, Julian, additional, Rajah, Maaran Michael, additional, Robinot, Remy, additional, Porrot, Françoise, additional, Albert, Mélanie, additional, Chen, Kuang-Yu, additional, Crescenzo, Bernadette, additional, Donati, Flora, additional, Anna, François, additional, Souque, Philippe, additional, Gransagne, Marion, additional, Bellalou, Jacques, additional, Nowakowski, Mireille, additional, Backovic, Marija, additional, Bouadma, Lila, additional, Fevre, Lucie Le, additional, Hingrat, Quentin Le, additional, Descamps, Diane, additional, Pourbaix, Annabelle, additional, Yazdanpanah, Yazdan, additional, Tondeur, Laura, additional, Besombes, Camille, additional, Ungeheuer, Marie-Noëlle, additional, Mellon, Guillaume, additional, Morel, Pascal, additional, Rolland, Simon, additional, Rey, Felix, additional, Behillil, Sylvie, additional, Enouf, Vincent, additional, Lemaitre, Audrey, additional, Créach, Marie-Aude, additional, Petres, Stephane, additional, Escriou, Nicolas, additional, Charneau, Pierre, additional, Fontanet, Arnaud, additional, Hoen, Bruno, additional, Bruel, Timothée, additional, Eloit, Marc, additional, Mouquet, Hugo, additional, Schwartz, Olivier, additional, and van der Werf, Sylvie, additional

Published
2020
Full Text
View/download PDF

50. Anti‐ HIV ‐1 antibodies trigger non‐lytic complement deposition on infected cells

Author

Dufloo, Jérémy, primary, Guivel‐Benhassine, Florence, additional, Buchrieser, Julian, additional, Lorin, Valérie, additional, Grzelak, Ludivine, additional, Dupouy, Emilie, additional, Mestrallet, Guillaume, additional, Bourdic, Katia, additional, Lambotte, Olivier, additional, Mouquet, Hugo, additional, Bruel, Timothée, additional, and Schwartz, Olivier, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results